Published in Mol Cell Biol on September 06, 2011
The 2 Faces of JNK Signaling in Cancer. Genes Cancer (2013) 1.00
miRNA regulated pathways in late stage murine lung development. BMC Dev Biol (2013) 0.93
SAPK pathways and p53 cooperatively regulate PLK4 activity and centrosome integrity under stress. Nat Commun (2013) 0.92
Deletions linked to TP53 loss drive cancer through p53-independent mechanisms. Nature (2016) 0.92
Sin3a acts through a multi-gene module to regulate invasion in Drosophila and human tumors. Oncogene (2012) 0.92
A graph theoretic approach to utilizing protein structure to identify non-random somatic mutations. BMC Bioinformatics (2014) 0.91
The structural pathway of interleukin 1 (IL-1) initiated signaling reveals mechanisms of oncogenic mutations and SNPs in inflammation and cancer. PLoS Comput Biol (2014) 0.84
Impaired JNK signaling cooperates with KrasG12D expression to accelerate pancreatic ductal adenocarcinoma. Cancer Res (2014) 0.81
In vivo gene manipulation reveals the impact of stress-responsive MAPK pathways on tumor progression. Cancer Sci (2015) 0.79
Structure-functional prediction and analysis of cancer mutation effects in protein kinases. Comput Math Methods Med (2014) 0.79
Recurrent MLK4 Loss-of-Function Mutations Suppress JNK Signaling to Promote Colon Tumorigenesis. Cancer Res (2015) 0.78
Anti- and Protumorigenic Effects of PPARγ in Lung Cancer Progression: A Double-Edged Sword. PPAR Res (2012) 0.77
Comparative transcriptomics reveals similarities and differences between astrocytoma grades. BMC Cancer (2015) 0.77
An exact algorithm for finding cancer driver somatic genome alterations: the weighted mutually exclusive maximum set cover problem. Algorithms Mol Biol (2016) 0.76
mTORC1 senses stresses: Coupling stress to proteostasis. Bioessays (2017) 0.75
Registered report: Diverse somatic mutation patterns and pathway alterations in human cancers. Elife (2016) 0.75
miR-141 promotes colon cancer cell proliferation by inhibiting MAP2K4. Oncol Lett (2017) 0.75
HELZ2 Is an IFN Effector Mediating Suppression of Dengue Virus. Front Microbiol (2017) 0.75
A method and server for predicting damaging missense mutations. Nat Methods (2010) 78.53
SIFT: Predicting amino acid changes that affect protein function. Nucleic Acids Res (2003) 52.26
Patterns of somatic mutation in human cancer genomes. Nature (2007) 38.41
Mammalian MAP kinase signalling cascades. Nature (2001) 18.89
Analysis of lung tumor initiation and progression using conditional expression of oncogenic K-ras. Genes Dev (2001) 15.97
Somatic activation of the K-ras oncogene causes early onset lung cancer in mice. Nature (2001) 10.56
Signatures of mutation and selection in the cancer genome. Nature (2010) 9.75
LKB1 modulates lung cancer differentiation and metastasis. Nature (2007) 7.80
Somatic mutations of the protein kinase gene family in human lung cancer. Cancer Res (2005) 7.66
The many faces of PPARgamma. Cell (2005) 6.24
How MAP kinases are regulated. J Biol Chem (1995) 6.04
Induction and apoptotic regression of lung adenocarcinomas by regulation of a K-Ras transgene in the presence and absence of tumor suppressor genes. Genes Dev (2001) 5.67
Colorectal cancer: mutations in a signalling pathway. Nature (2005) 5.42
Tumor induction by an endogenous K-ras oncogene is highly dependent on cellular context. Cancer Cell (2003) 5.17
Insulin-like growth factor-I activates gene transcription programs strongly associated with poor breast cancer prognosis. J Clin Oncol (2008) 3.74
Contextual extracellular cues promote tumor cell EMT and metastasis by regulating miR-200 family expression. Genes Dev (2009) 3.58
Integrative genomic and proteomic analyses identify targets for Lkb1-deficient metastatic lung tumors. Cancer Cell (2010) 3.40
Transcriptional activation by peroxisome proliferator-activated receptor gamma is inhibited by phosphorylation at a consensus mitogen-activated protein kinase site. J Biol Chem (1997) 3.19
Activation of the peroxisome proliferator-activated receptor gamma promotes the development of colon tumors in C57BL/6J-APCMin/+ mice. Nat Med (1998) 3.13
Activators of the nuclear receptor PPARgamma enhance colon polyp formation. Nat Med (1998) 2.90
K-ras activation generates an inflammatory response in lung tumors. Oncogene (2006) 2.78
Loss-of-function mutations in PPAR gamma associated with human colon cancer. Mol Cell (1999) 2.71
Distinguishing cancer-associated missense mutations from common polymorphisms. Cancer Res (2007) 2.57
Design and analysis issues in genome-wide somatic mutation studies of cancer. Genomics (2008) 1.95
Role of mitogen-activated protein kinase kinase 4 in cancer. Oncogene (2007) 1.79
T0070907, a selective ligand for peroxisome proliferator-activated receptor gamma, functions as an antagonist of biochemical and cellular activities. J Biol Chem (2002) 1.75
Pten inactivation accelerates oncogenic K-ras-initiated tumorigenesis in a mouse model of lung cancer. Cancer Res (2008) 1.58
A genetic mouse model for metastatic lung cancer with gender differences in survival. Oncogene (2007) 1.55
HIF2alpha cooperates with RAS to promote lung tumorigenesis in mice. J Clin Invest (2009) 1.49
Suppression of Ras-stimulated transformation by the JNK signal transduction pathway. Genes Dev (2003) 1.48
The p38 kinases MKK4 and MKK6 suppress metastatic colonization in human ovarian carcinoma. Cancer Res (2006) 1.43
Mitogen-activated protein kinase kinase 4/stress-activated protein/Erk kinase 1 (MKK4/SEK1), a prostate cancer metastasis suppressor gene encoded by human chromosome 17. Cancer Res (1999) 1.43
Mutations in the tumor suppressors Smad2 and Smad4 inactivate transforming growth factor beta signaling by targeting Smads to the ubiquitin-proteasome pathway. Proc Natl Acad Sci U S A (2000) 1.43
Mitogen-activated protein kinase kinase 4 (MKK4) acts as a metastasis suppressor gene in human ovarian carcinoma. Cancer Res (2002) 1.33
c-Jun N-terminal kinase is activated in non-small-cell lung cancer and promotes neoplastic transformation in human bronchial epithelial cells. Oncogene (2006) 1.33
Cancer driver mutations in protein kinase genes. Cancer Lett (2008) 1.24
TSC1 loss synergizes with KRAS activation in lung cancer development in the mouse and confers rapamycin sensitivity. Oncogene (2009) 1.16
Evidence of MKK4 pro-oncogenic activity in breast and pancreatic tumors. Oncogene (2004) 1.14
Targeted deletion of the mitogen-activated protein kinase kinase 4 gene in the nervous system causes severe brain developmental defects and premature death. Mol Cell Biol (2007) 1.11
Peroxisome proliferator-activated receptor gamma promotes epithelial to mesenchymal transformation by Rho GTPase-dependent activation of ERK1/2. J Biol Chem (2006) 1.08
Stress pathway activation induces phosphorylation of retinoid X receptor. J Biol Chem (2000) 1.05
The mitogen-activated protein kinase kinase 4 has a pro-oncogenic role in skin cancer. Cancer Res (2010) 0.99
Mutant products of the NF2 tumor suppressor gene are degraded by the ubiquitin-proteasome pathway. J Biol Chem (2002) 0.98
A peroxisome proliferator-activated receptor gamma antagonist induces vimentin cleavage and inhibits invasion in high-grade hepatocellular carcinoma. Oncol Rep (2007) 0.97
Isolation of Cry1Ab protein mutants of Bacillus thuringiensis by a highly efficient PCR site-directed mutagenesis system. FEMS Microbiol Lett (1996) 0.96
Transcriptional profiling of non-small cell lung cancer cells with activating EGFR somatic mutations. PLoS One (2007) 0.95
Destabilizing missense mutations in the tumour suppressor protein p53 enhance its ubiquitination in vitro and in vivo. Biochem J (2006) 0.89
Inhibition of peroxisome proliferator-activated receptor gamma activity suppresses pancreatic cancer cell motility. Cancer Sci (2008) 0.88
c-Jun NH2-terminal kinase activating kinase 1/mitogen-activated protein kinase kinase 4-mediated inhibition of SKOV3ip.1 ovarian cancer metastasis involves growth arrest and p21 up-regulation. Cancer Res (2008) 0.87
Loss of MKK4 expression in ovarian cancer: a potential role for the epithelial to mesenchymal transition. Int J Cancer (2011) 0.86
MKK4/SEK1 is negatively regulated through a feedback loop involving the E3 ubiquitin ligase itch. J Biol Chem (2009) 0.83
Crystal structures of MKK4 kinase domain reveal that substrate peptide binds to an allosteric site and induces an auto-inhibition state. Biochem Biophys Res Commun (2010) 0.82
A second generation human haplotype map of over 3.1 million SNPs. Nature (2007) 85.39
A draft sequence of the rice genome (Oryza sativa L. ssp. indica). Science (2002) 42.78
Somatic mutations affect key pathways in lung adenocarcinoma. Nature (2008) 30.02
Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer. Lancet (2005) 29.45
Landscape of transcription in human cells. Nature (2012) 20.18
Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy (2012) 20.08
Genome-wide detection and characterization of positive selection in human populations. Nature (2007) 17.27
Characterizing the cancer genome in lung adenocarcinoma. Nature (2007) 16.48
Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst (2005) 13.00
The developmental transcriptome of Drosophila melanogaster. Nature (2010) 11.85
A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene. Cell (2009) 8.64
The Genomes of Oryza sativa: a history of duplications. PLoS Biol (2005) 7.67
The BATTLE trial: personalizing therapy for lung cancer. Cancer Discov (2011) 7.57
Cell-free formation of RNA granules: low complexity sequence domains form dynamic fibers within hydrogels. Cell (2012) 6.83
Immortalization of human bronchial epithelial cells in the absence of viral oncoproteins. Cancer Res (2004) 5.57
A genetic variation map for chicken with 2.8 million single-nucleotide polymorphisms. Nature (2004) 5.24
Yersinia YopJ acetylates and inhibits kinase activation by blocking phosphorylation. Science (2006) 4.71
KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer. Clin Cancer Res (2007) 4.45
Integrative genomics analysis reveals silencing of beta-adrenergic signaling by polycomb in prostate cancer. Cancer Cell (2007) 4.43
Somatic mutations of the HER2 kinase domain in lung adenocarcinomas. Cancer Res (2005) 4.25
Fate tracing reveals the endothelial origin of hematopoietic stem cells. Cell Stem Cell (2008) 4.17
An encyclopedia of mouse DNA elements (Mouse ENCODE). Genome Biol (2012) 4.15
MDA-MB-435 cells are derived from M14 melanoma cells--a loss for breast cancer, but a boon for melanoma research. Breast Cancer Res Treat (2006) 4.04
Aberrant epidermal growth factor receptor signaling and enhanced sensitivity to EGFR inhibitors in lung cancer. Cancer Res (2005) 3.98
B7-H1 blockade augments adoptive T-cell immunotherapy for squamous cell carcinoma. Cancer Res (2003) 3.96
Treatment of non-small-cell lung cancer with erlotinib or gefitinib. N Engl J Med (2011) 3.74
Prognostically relevant gene signatures of high-grade serous ovarian carcinoma. J Clin Invest (2012) 3.64
Contextual extracellular cues promote tumor cell EMT and metastasis by regulating miR-200 family expression. Genes Dev (2009) 3.58
A SUMOylation-dependent transcriptional subprogram is required for Myc-driven tumorigenesis. Science (2011) 3.49
An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance. Clin Cancer Res (2012) 3.48
PIK3CA mutations and copy number gains in human lung cancers. Cancer Res (2008) 3.42
TAp63 suppresses metastasis through coordinate regulation of Dicer and miRNAs. Nature (2010) 3.37
Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function. Cancer Res (2008) 3.32
Activation of multiple proto-oncogenic tyrosine kinases in breast cancer via loss of the PTPN12 phosphatase. Cell (2011) 3.27
Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. N Engl J Med (2015) 3.00
Complete genome sequence of Yersinia pestis strain 91001, an isolate avirulent to humans. DNA Res (2004) 2.95
Effect of KRAS oncogene substitutions on protein behavior: implications for signaling and clinical outcome. J Natl Cancer Inst (2012) 2.79
Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1. Cancer Discov (2012) 2.68
Docking motif interactions in MAP kinases revealed by hydrogen exchange mass spectrometry. Mol Cell (2004) 2.55
The genome of the pear (Pyrus bretschneideri Rehd.). Genome Res (2012) 2.55
Aldehyde dehydrogenase activity selects for lung adenocarcinoma stem cells dependent on notch signaling. Cancer Res (2010) 2.54
Crystal structures of MAP kinase p38 complexed to the docking sites on its nuclear substrate MEF2A and activator MKK3b. Mol Cell (2002) 2.51
Lack of PTEN expression in non-small cell lung cancer could be related to promoter methylation. Clin Cancer Res (2002) 2.50
Amplification of chromosomal segment 4q12 in non-small cell lung cancer. Cancer Biol Ther (2009) 2.47
Accurate identification of human Alu and non-Alu RNA editing sites. Nat Methods (2012) 2.47
The transcriptional diversity of 25 Drosophila cell lines. Genome Res (2010) 2.47
Foxa1 and Foxa2 regulate multiple phases of midbrain dopaminergic neuron development in a dosage-dependent manner. Development (2007) 2.40
Global gene expression analysis of reactive stroma in prostate cancer. Clin Cancer Res (2009) 2.34
EGFR tyrosine kinase domain mutations are detected in histologically normal respiratory epithelium in lung cancer patients. Cancer Res (2005) 2.17
Regulation of WNK1 by an autoinhibitory domain and autophosphorylation. J Biol Chem (2002) 2.16
Nrf2 and Keap1 abnormalities in non-small cell lung carcinoma and association with clinicopathologic features. Clin Cancer Res (2010) 2.14
Retracted Aberrant methylation of Reprimo in human malignancies. Int J Cancer (2005) 2.13
COUP-TFII inhibits TGF-β-induced growth barrier to promote prostate tumorigenesis. Nature (2012) 2.11
miR-93, miR-98, and miR-197 regulate expression of tumor suppressor gene FUS1. Mol Cancer Res (2009) 2.11
Proinflammatory role for let-7 microRNAS in experimental asthma. J Biol Chem (2010) 2.08
TNFα facilitates clonal expansion of JAK2V617F positive cells in myeloproliferative neoplasms. Blood (2011) 2.07
Integration of molecular profiling into the lung cancer clinic. Clin Cancer Res (2009) 2.06
High-grade serous ovarian cancer arises from fallopian tube in a mouse model. Proc Natl Acad Sci U S A (2012) 2.03
A Semantic Web management model for integrative biomedical informatics. PLoS One (2008) 2.02
Docking interactions induce exposure of activation loop in the MAP kinase ERK2. Structure (2006) 2.01
Inhibition of mammalian target of rapamycin reverses alveolar epithelial neoplasia induced by oncogenic K-ras. Cancer Res (2005) 2.01
Regulation of cellular functions by the ERK5 signalling pathway. Cell Signal (2006) 1.98
Structure-guided lead optimization of triazolopyrimidine-ring substituents identifies potent Plasmodium falciparum dihydroorotate dehydrogenase inhibitors with clinical candidate potential. J Med Chem (2011) 1.94
Spontaneous atherosclerosis in aged lipoprotein lipase-deficient mice with severe hypertriglyceridemia on a normal chow diet. Circ Res (2007) 1.94
A link between mir-100 and FRAP1/mTOR in clear cell ovarian cancer. Mol Endocrinol (2010) 1.94
High expression of ErbB family members and their ligands in lung adenocarcinomas that are sensitive to inhibition of epidermal growth factor receptor. Cancer Res (2005) 1.94
Oncogene mutations, copy number gains and mutant allele specific imbalance (MASI) frequently occur together in tumor cells. PLoS One (2009) 1.94
Identification of genes modulated in rheumatoid arthritis using complementary DNA microarray analysis of lymphoblastoid B cell lines from disease-discordant monozygotic twins. Arthritis Rheum (2006) 1.92
Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents. Clin Cancer Res (2012) 1.92
Properties of WNK1 and implications for other family members. J Biol Chem (2005) 1.89
JNK and PTEN cooperatively control the development of invasive adenocarcinoma of the prostate. Proc Natl Acad Sci U S A (2012) 1.88
The third conformation of p38α MAP kinase observed in phosphorylated p38α and in solution. Structure (2010) 1.88
Spinal cord stimulation-induced analgesia: electrical stimulation of dorsal column and dorsal roots attenuates dorsal horn neuronal excitability in neuropathic rats. Anesthesiology (2010) 1.87
Cleavage of fibrinogen by proteinases elicits allergic responses through Toll-like receptor 4. Science (2013) 1.87
Crystal structure of domain-swapped STE20 OSR1 kinase domain. Protein Sci (2009) 1.87
High expression of ligands for chemokine receptor CXCR2 in alveolar epithelial neoplasia induced by oncogenic kras. Cancer Res (2006) 1.84
Crystal structure of the kinase domain of WNK1, a kinase that causes a hereditary form of hypertension. Structure (2004) 1.82
Natural competence in the hyperthermophilic archaeon Pyrococcus furiosus facilitates genetic manipulation: construction of markerless deletions of genes encoding the two cytoplasmic hydrogenases. Appl Environ Microbiol (2011) 1.81
SRC-family kinases are activated in non-small cell lung cancer and promote the survival of epidermal growth factor receptor-dependent cell lines. Am J Pathol (2007) 1.79
An Integrated Metabolic Atlas of Clear Cell Renal Cell Carcinoma. Cancer Cell (2016) 1.79
Dual regulation of genes involved in acetoin biosynthesis and motility/biofilm formation by the virulence activator AphA and the acetate-responsive LysR-type regulator AlsR in Vibrio cholerae. Mol Microbiol (2005) 1.78
Human lung cancer cells grown on acellular rat lung matrix create perfusable tumor nodules. Ann Thorac Surg (2012) 1.75
Phosphatidylinositol 3-kinase mediates bronchioalveolar stem cell expansion in mouse models of oncogenic K-ras-induced lung cancer. PLoS One (2008) 1.72
Identification of gene signatures and molecular markers for human lung cancer prognosis using an in vitro lung carcinogenesis system. Cancer Prev Res (Phila) (2009) 1.71
Sex determining region Y-Box 2 (SOX2) is a potential cell-lineage gene highly expressed in the pathogenesis of squamous cell carcinomas of the lung. PLoS One (2010) 1.69
Evolving concepts in the pathology and computed tomography imaging of lung adenocarcinoma and bronchioloalveolar carcinoma. J Clin Oncol (2005) 1.69
Quantity and quality of trabecular bone in the femur are enhanced by a strongly anabolic, noninvasive mechanical intervention. J Bone Miner Res (2002) 1.68
The crystal structure of AphB, a virulence gene activator from Vibrio cholerae, reveals residues that influence its response to oxygen and pH. Mol Microbiol (2012) 1.64
The fusion peptide of Semliki Forest virus associates with sterol-rich membrane domains. J Virol (2002) 1.62
HER family receptor abnormalities in lung cancer brain metastases and corresponding primary tumors. Clin Cancer Res (2009) 1.61
Bexarotene plus erlotinib suppress lung carcinogenesis independent of KRAS mutations in two clinical trials and transgenic models. Cancer Prev Res (Phila) (2011) 1.61
Inhibitory effect of the antimalarial agent artesunate on collagen-induced arthritis in rats through nuclear factor kappa B and mitogen-activated protein kinase signaling pathway. Transl Res (2012) 1.61